Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study

Table 2 Behaviour of urinary parameters before and after 2-day treatment with dapagliflozin or hydrochlorothiazide

	Dapagliflozin (n = 16)		Hydrochlorothiazide (n = 10)		p value (time × treatment interaction)
	Visit 0	Visit 1	Visit 0	Visit 1	p value (time × treatment interaction)
Diuresis (ml/24 h)	1400 [750]	2000 [750]^a	1250 [150]	2100 [700]	0.47
u-sodium (mEq/24 h)	175 [107]	180 [57]	129 [96]	141 [173]	0.31
u-potassium (mEq/24 h)	60 [37]	64 [36]	56 [23]	59 [49]	0.10
u-calcium (mg/24 h)	220 [238]	158 [229]	250 [120]	93 [260]	0.47
u-chloride (mEq/24 h)	183 [113]	167 [79]	105 [121]	130 [163]	0.30
u-magnesium (mg/24 h)	70 [86]	72 [88]	100 [36]	78 [103]	0.34
u-osmolarity (mOsm/l)	687 ± 325	877 ± 230^b	512 ± 76	377 ± 179	0.15
Glycosuria (mg/24 h)	406 [4224]	70,630 [40,110]^ab	100 [84]	45 [135]	< 0.001
Osmolar clearance (ml/24 h)	2369 [3509]	5971 [3251]^a	1982 [664]	2063 [2922]	0.28
Free water clearance (ml/24 h)	− 1119 [3441]	− 4221 [3549]^a	− 757 [538]	36 [2222]	0.17
Na fractional excretion	0.89 ± 0.32	0.97 ± 0.34	0.62 ± 0.17	0.79 ± 0.07	0.72

Data are mean ± SD, or median [IQ]
s serum, u urinary
^ap < 0.05 vs V0
^bp < 0.05 vs HCT (Bonferroni post hoc comparison). The p value is for time × treatment interaction obtained by repeated measures ANOVA

ISSN: 1475-2840